MLMC Therapeutics ApS: Financial statements 2023
CVR: 41277688
Source: annual report 2023, Danish Business Authority
01/01/2023 – 31/12/2023
MLMC Therapeutics ApS (CVR 41277688) has filed annual accounts for 2023. In 2023, the company reported a gross profit of DKK -25,639 and a net result of DKK -122,678 compared with DKK -90,240 the year before. Equity in the 2023 report amounted to DKK -204,548.
- Gross Profit
- DKK -25,639
- Profit/Loss
- DKK -122,678
- Equity
- DKK -204,548
- Total Assets
- DKK 216,840
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2023 | - | -26 t. | -123 t. | -205 t. | - |
| 2022 | - | -30 t. | -90 t. | -82 t. | - |
| 2021 | - | -20 t. | -54 t. | 8 t. | 0 |
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record — straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2023
MLMC Therapeutics ApS has published its annual report for 2022. Gross profit came to DKK -29,822, and the net result was DKK -90,240.
As of May 1, 2023, A/S PSE 17 NR. 1056 has stepped down as auditor of MLMC Therapeutics ApS.
About MLMC Therapeutics ApS
MLMC Therapeutics ApS is a Danish company of the type Anpartsselskab based in Kastrup, founded in 2020. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Michael Henrik Stadi. The board consists of Martin Kiener (chair), Hanne Damgaard Jensen and Peter Gudmund Nielsen. The company's owners include Ritika Singh Petersen, Sriram Thoppe Rajendran and FOMT HOLDING ApS. According to the 2021 annual report, the company had an average of 0 employees. In 2025, the company reported a gross profit of DKK -30,768 and a net result of DKK -144,214 compared with DKK -134,525 the year before. Equity in the 2025 report amounted to DKK -483,287.